Citations

Clear

626 citation(s) found for "Mehta, SH".

Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation therapy oncology group trial 9402
Wang, M., Cairncross, Gregory, Shaw, Edward , Jenkins, Robert B. , Scheithauer, B. W., Brachman, David, Buckner, Jan C. , Souhami, Luís, Curran, Walter J. , Laperrière, Normand , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: e20519-e20519

10.1200/jco.2009.27.15_suppl.e20519 Get It

e20519 Background: Radiation Therapy Oncology Group 9402 compared PCV chemotherapy plus radiation therapy (PCV+RT) versus RT alone for anaplastic oligodendroglioma. Here we report 1) longitudinal changes in cognition and quality of life, 2) effects of patient factors and treatments on cognition, quality of life and survival, and 3) prognostic implications of cognition and quality of life. Methods: Cognition was assessed by Mini Mental Status Examination (MMSE) and quality of life by Brain-Quality of Life (B-QOL) by repeat assessments. Scores were analyzed for survivors and within five years of death. Shared parameter models evaluated MMSE/B-QOL with survival. Results: For survivors, MMSE and B-QOL scores were similar longitudinally and between treatments. For those dying within 5 years, MMSE scores were stable initially, while B-QOL scores decreased; both declined rapidly in the last year of life and similarly between arms. In the aggregate, scores decreased over time (P=0.0413 for MMSE; P=0.0016 for B-QOL) and were superior with age < 50 years (P<0.001 for MMSE; P=0.0554 for B-QOL) and KPS 80–100 (P<0.001). Younger age and higher KPS were associated with longer survival. After adjusting for patient factors and drop-out, survival was longer after PCV+RT (HR=0.66, 95% CI=0.49–0.9, P=0.0084; HR=0.74, 95% CI=0.54–1.01, P=0.0592) in models with MMSE and B-QOL. There were no differences in MMSE and B-QOL scores between arms (P=0.4752 and P=0.2767, respectively); higher scores predicted longer survival. Conclusions: MMSE and B-QOL scores held steady in both arms for survivors. For those who died, B-QOL scores declined slowly until the last year of life, then rapidly. Younger, fitter patients had better MMSE and B-QOL scores and longer survival. No significant financial relationships to disclose.
Prospective evaluation of the utility of magnetic resonance imaging in patients with non‐MRI‐conditional pacemakers and defibrillators
Padmanabhan, Deepak , Kella, Danesh , Isath, Ameesh , Tandon, Nidhi , Mulpuru, Siva K. , Deshmukh, Abhishek , Mehta, Ramila A. , Dalzell, Connie, Olson, Nora E., Felmlee, Joel P. , Jondal, Mary Lou, Asirvatham, Samuel J. , Watson, Robert E. , Cha, Yong‐Mei , Friedman, Paul A. , Mulpuru, Siva K , Kapa, Suraj , Mehta, Ramila, Olson, Nora, Felmlee, Joel, Jondal, Mary L, Asirvatham, Samuel J , Cha, Yong-Mei , Friedman, Paul A , Kella, Danesh K , Kapa, Suraj

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 5, 2020 | Volume: 31 | Issue: 11 | Pages: 2931-2939

10.1111/jce.14705 | PMID 32757438 Get It

AbstractBackgroundMagnetic resonance imaging (MRI) in patients with legacy cardiovascular implantable electronic devices (CIEDs) in situ is likely underutilized. We hypothesized the clinical benefit of MRI would outweigh the risks in legacy CIED patients.MethodsThis is a single‐center retrospective study that evaluated and classified the utility of MRI using a prospectively maintained database. The outcomes were classified as aiding in diagnosis, treatment, or both for the patients attributable to the MRI. We then assessed the incidence of adverse effects (AE) when the MRI was performed.ResultsIn 668, MRIs performed on 479 patients, only 13 (1.9%) MRIs did not aid in the diagnosis or treatment of the patient. Power‐on reset events without clinical sequelae in three scans (0.45%) were the only AE. The probability of an adverse event happening without any benefit from the MRI scan was 1.1 × 10−4. A maximum benefit in diagnosis using MRI was obtained in ruling out space‐occupying lesions (121/185 scans, 65.4%). Scans performed in patients for elucidating answers to queries in treatment were most frequently done for disease staging at long term follow‐up (167/470 scans, 35.5%). Conservative treatment (184/470 scans, 39%) followed by medication changes (153/470 scans, 28.7%) were the most common treatment decisions made.ConclusionsThe utility of MRI in patients with non‐MRI‐conditional CIEDs far outweighs the risk of adverse events when imaging is done in the context of a multidisciplinary program that oversees patient safety.
30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
Gondi, Vinai , Brown, Paul D. , Ahluwalia, Manmeet S. , Ahluwalia, Manmeet S , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology Advances | August 4, 2020 | Volume: 2 | Issue: Supplement_2 | Pages: ii5-ii5

10.1093/noajnl/vdaa073.018 Get It

Abstract BACKGROUND Tumor Treating Fields (TTFields) are non-invasive, loco-regional, anti-mitotic treatment modality comprising alternating electric fields. TTFields have demonstrated efficacy in preclinical non-small cell lung cancer (NSCLC) models. TTFields treatment to the brain was safe and extended overall survival in newly-diagnosed glioblastoma. The objective of the METIS study [NCT02831959] is evaluation of the efficacy and safety of TTFields in NSCLC patients with brain metastases. METHODS NSCLC patients (N=270) with 1–10 brain metastases were randomized 1:1 to stereotactic radio surgery (SRS) followed by continuous TTFields ((150 kHz, &gt; 18 hours/day) within 7 days of SRS or supportive care. The portable device delivered TTFields to the brain using 4 transducer arrays, while patients received the best standard-of-care for systemic disease. Patients were followed every two months until second intracranial progression. Key inclusion criteria: KPS ≥70, new diagnosis of 1 inoperable or 2–10 supra- and/or infratentorial brain metastases from NSCLC amenable to SRS; and optimal therapy for extracranial disease. Prior WBRT, surgical resection of metastases, or recurrent brain metastases were exclusionary. Primary endpoint was time to 1st intracranial progression. Secondary endpoints included time to neurocognitive failure (HVLT, COWAT and TMT), overall survival, radiological response rate (RANO-BM and RECIST V1.1); quality-of-life; adverse events; time to first/second intracranial progression for patients with 1–4 and 5–10 brain metastases; bi-monthly intracranial progression rate from 2–12 months; and time to second intracranial and distant progression. The sample size (N=270) was calculated using a log-rank test (Lakatos 1988 and 2002) with 80% power at two sided alpha of 0.05 to detect a hazard ratio of 0.57. On September, 2019, an independent Data Monitoring Committee (DMC) reviewed METIS trial data collected to that point. The DMC concluded that no unexpected safety issues had emerged and recommended continuation of the METIS study as planned.
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Bartlett, Nancy L. , Herrera, Alex F. , Domingo‐Doménech, Eva , Mehta, Amitkumar , Forero‐Torres, Andres , García‐Sánz, Ramón , Armand, Philippe , Devata, Sumana, Izquierdo, Antonia Rodríguez, Lossos, Izidore S. , Reeder, Craig B. , Sher, Taimur , Chen, Robert , Schwarz, Sylvia E., Alland, Leila, Strassz, András, Prier, Kim, Choe-Juliak, Cassandra, Ansell, Stephen M. , Reeder, Craig, Bartlett, Nancy L , Garcia-Sanz, Ramon , Mehta, Amitkumar , Domingo-Domenech, Eva

Mayo Clinic

Blood | July 30, 2020 | Volume: 136 | Issue: 21 | Pages: 2401-2409

10.1182/blood.2019004701 | PMID 32730586 Get It

Abstract In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the anti-programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy and are playing an increasingly prominent role in treatment. The CD30/CD16A-bispecific antibody AFM13 is an innate immune cell engager, a first-in-class, tetravalent antibody, designed to create a bridge between CD30 on HL cells and the CD16A receptor on natural killer cells and macrophages, to induce tumor cell killing. Early studies of AFM13 have demonstrated signs of efficacy as monotherapy for patients with R/R HL and the combination of AFM13 with pembrolizumab represents a rational new treatment modality. Here, we describe a phase 1b, dose-escalation study to assess the safety and preliminary efficacy of AFM13 in combination with pembrolizumab in patients with R/R HL. The primary objective was estimating the maximum tolerated dose; the secondary objectives were to assess safety, tolerability, antitumor efficacy, pharmacokinetics, and pharmacodynamics. In this heavily pretreated patient population, treatment with the combination of AFM13 and pembrolizumab was generally well tolerated, with similar safety profiles compared to the known profiles of each agent alone. The combination of AFM13 with pembrolizumab demonstrated an objective response rate of 88% at the highest treatment dose, with an 83% overall response rate for the overall population. Pharmacokinetic assessment of AFM13 in the combination setting revealed a half-life of up to 20.6 hours. This proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This phase 1b study was registered at www.clinicaltrials.gov as NCT02665650.
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
Bell, Erica H. , Shaw, Edward G. , Buckner, Jan C. , Barger, Geoffrey, Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , McElroy, Joseph P., Fleming, Jessica L. , Timmers, Cynthia , Salavaggione, Andrea L., Aldape, Kenneth , Brachman, David, Gertler, Stanley Z., Murtha, Albert , Schultz, Christopher J. , Hunter, G.K., Crocker, Ian , Won, Minhee , Chakravarti, Arnab , Chakravarti, Arnab , Chakravarti, Arnab , Zhang, Jianwen , Mehta, Minesh P. , Gilbert, Mark R. , Becker, Aline Paixão , Liu, Ziyan , Johnson, David, Laack, Nadia N.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2020 | Volume: 38 | Issue: 29 | Pages: 3407-3417

10.1200/jco.19.02983 | PMID 32706640 Get It

PURPOSENRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375 ) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802.METHODSIDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates.RESULTSOf the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH-wild type, 43 (41%) were IDH-mutant/non-codeleted, and 37(35%) were IDH-mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH-mutant/non-codeleted and IDH-mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH-wild-type subgroup.CONCLUSIONThis study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH-mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.
Use of Biomarkers to Detect and Manage Acute Kidney Injury: Has Progress Stalled?
Kellum, John A. , Mehta, Ravindra L. , Parikh, Chirag R. , Mehta, Ravindra L , Parikh, Chirag R , Kellum, John A , Lieske, John C. , Kashani, Kianoush , Koyner, Jay L.

Mayo Clinic

Clinical Chemistry | July 17, 2020 | Volume: 66 | Issue: 2 | Pages: 271-276

10.1093/clinchem/hvz026 | PMID 32040587 Get It

A Study of Combined Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration and Transbronchial Cryobiopsy (E-TBNA/TBCB) to Define the Significance of Enlarged Mediastinal Lymph Nodes in Patients with Interstitial Lung Disease: An Epiphenomenon or
Yadav, Poonam , Kalpakam, Hariprasad , T.V, Haridas, Shivakumar, S., Tazelaar, Henry D. , Mehta, Ravindra , Bhat, Rajani Surendar , Yadav, P., Tazelaar, Henry D.

Mayo Clinic

A38. GRANULOMATOUS LUNG DISEASE | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1539-A1539

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1539 Get It

Backward Protective Stepping During Dual-Task Scenarios in People With Parkinson’s Disease: A Pilot Study
Peterson, Daniel S. , Barajas, Jordan S., Denney, Linda, Mehta, Shyamal H. , Peterson, Daniel

Mayo Clinic

Neurorehabilitation and Neural Repair | July 7, 2020 | Volume: 34 | Issue: 8 | Pages: 702-710

10.1177/1545968320935814 | PMID 32633614 Get It

Introduction. Reactive movements in response to a loss of balance are altered in people with Parkinson’s disease (PD) and are critical for fall prevention. Further, falls are more common while attention is divided. Although divided attention has been shown to impact postural responses in healthy older adults, the impact of dividing attention on reactive balance, and the natural prioritization across postural and cognitive tasks in people with PD is largely unknown. Objectives. To characterize (1) the impact of a secondary cognitive task on reactive postural control and (2) the prioritization across stepping and cognitive tasks in people with PD. Methods. Sixteen people with PD and 14 age-matched controls underwent step-inducing, support-surface perturbations from stance, with and without an auditory Stroop secondary cognitive task. Cognitive, neuromuscular, and protective stepping performance were calculated for single and dual task scenarios. Results. In PD and control participants, cognitive reaction times ( P = .001) and muscle onset latency ( P = .007), but not protective step outcomes ( P > .12 for all) were worse during dual tasking compared with single-task scenarios. Both PD and control groups prioritized the protective stepping task over the cognitive task. Overall, people with PD exhibited worse first-step margin of stability (a measure of protective step performance) than controls ( P = .044). Conclusion. This study provides preliminary evidence that people with PD, like age-matched controls, exhibit cognitive and neuromuscular, but not protective step, dual-task interference. The lack of dual-task interference on step performance indicates a postural prioritization for PD and healthy older adults during dual-task protective stepping.
Pathophysiological Mechanisms Underlying Excess Risk for Diabetes and Cardiovascular Disease in South Asians: The Perfect Storm
Singh, Sumitabh , Mahtta, Dhruv , Bittner, Vera , Sperling, Laurence , Mehta, Anurag , Saeed, Anum , Virani, Salim S.

Mayo Clinic

Current Diabetes Reviews | July 3, 2020 | Volume: 17 | Issue: 9 | Pages: No page available

10.2174/1573399816666200703182458 | PMID 32619174 Get It

Background: South Asians are at a significantly increased risk of type 2 diabetes (T2D) and cardiovascular disease (CVD), are diagnosed at relatively younger ages, and exhibit more severe disease phenotypes as compared with other ethnic groups. The pathophysiological mechanisms underlying T2D and CVD risk in South Asians are multifactorial and intricately related. Method: A narrative review of the pathophysiology of excess risk of T2D and CVD in South Asians. Result: T2D and CVD have shared risk factors that encompass biological factors (early life influences, impaired glucose metabolism, and adverse body composition) as well as behavioral and environmental risk factors (diet, sedentary behavior, tobacco use, and social determinants of health). Genetics and epigenetics also play a role in explaining the increased risk of T2D and CVD among South Asians. Additionally, South Asians harbor several lipid abnormalities including high concentration of small-dense low-density lipoprotein (LDL) particles, elevated triglycerides, low high-density lipoprotein (HDL)- cholesterol levels, dysfunctional HDL particles, and elevated lipoprotein(a) that predispose them to CVD. Conclusion: In this comprehensive review, we have discussed risk factors that provide insights into the pathophysiology of excess risk of T2D and CVD in South Asians.
Effect of Anatomic Segment Involvement on Stereotactic Radiosurgery for Facial Nerve Schwannomas: An International Multicenter Cohort Study
Mehta, Gautam U. , Leković, Gregory P. , Slattery, William H. , Brackmann, Derald E., Long, Hao , Kano, Hideyuki , Mureb, Monica , Bernstein, Kenneth , Langlois, Anne-Marie, Mathieu, David , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Emad, Reem M. , Mohammed, Nasser , Urgošík, Dušan, Liščák, Roman , Lee, Cheng‐Chia , Montazeripouragha, Amanallah , Joshi, Krishna C. , Barnett, Gene H. , Lunsford, L. Dade , Sheehan, Jason P. , Mehta, Gautam U , Mathieu, David , Kondziolka, Douglas , Langlois, Anne-Marie, Reda, Wael A. , Yang, Huai‐Che , Kaufmann, Anthony M. , Trifiletti, Daniel M.

Mayo Clinic

Neurosurgery | June 19, 2020 | Volume: 88 | Issue: 1 | Pages: E91-E98

10.1093/neuros/nyaa313 | PMID 32687577 Get It

Abstract BACKGROUND Facial nerve schwannomas are rare, challenging tumors to manage due to their nerve of origin. Functional outcomes after stereotactic radiosurgery (SRS) are incompletely defined. OBJECTIVE To analyze the effect of facial nerve segment involvement on functional outcome for these tumors. METHODS Patients who underwent single-session SRS for facial nerve schwannomas with at least 3 mo follow-up at 11 participating centers were included. Preoperative and treatment variables were recorded. Outcome measures included radiological tumor response and neurological function. RESULTS A total of 63 patients (34 females) were included in the present study. In total, 75% had preoperative facial weakness. Mean tumor volume and margin dose were 2.0 ± 2.4 cm 3 and 12.2 ± 0.54 Gy, respectively. Mean radiological follow-up was 45.5 ± 38.9 mo. Progression-free survival at 2, 5, and 10 yr was 98.1%, 87.2%, and 87.2%, respectively. The cumulative proportion of patients with regressing tumors at 2, 5, and 10 yr was 43.1%, 63.6%, and 63.6%, respectively. The number of involved facial nerve segments significantly predicted tumor progression ( P = .04). Facial nerve function was stable or improved in 57 patients (90%). Patients with involvement of the labyrinthine segment of the facial nerve were significantly more likely to have an improvement in facial nerve function after SRS ( P = .03). Hearing worsened in at least 6% of patients. Otherwise, adverse radiation effects included facial twitching (3 patients), facial numbness (2 patients), and dizziness (2 patients). CONCLUSION SRS for facial nerve schwannomas is effective and spares facial nerve function in most patients. Some patients may have functional improvement after treatment, particularly if the labyrinthine segment is involved.